Sustained Benefit With Sacituzumab Govitecan Following CPI in Platinum-Ineligible mUC
February 17th 2023Sacituzumab govitecan-hziy demonstrated a promising objective response rate in platinum-ineligible patients with metastatic urothelial cancer after progression on an immune checkpoint inhibitor.
Read More
Ra-223 Demonstrates Safety, Efficacy in Managing Bone Metastases in Prostate Cancer
February 17th 2023Patients diagnosed with bone metastatic, castration-resistant prostate cancer and treated with radium-223 showed lower incidences of treatment-related adverse events or treatment discontinuation, particularly when used in the front-line setting.
Read More
Acceptable Safety Seen With Orca-Q in the Haplo SCT Setting for High-risk Hematologic Malignancies
February 17th 2023At 1 year, the GVHD-and–relapse-free survival achieved with Orca-Q was 75%, which was noted to compare favorably with prior data reported in context of myeloablative conditioning , haploidentical stem cell transplant, and posttransplant cyclophosphamide.
Read More
Cytopenias Did Not Affect Ruxolitinib Efficacy in REACH2 Post Hoc Analysis
February 17th 2023Ruxolitinib elicited higher responses at day 28 compared with best available therapy in most cytopenia-based subgroups and had durable responses at day 56, according to a post hoc analysis of the REACH2 trial.
Read More
Ruxolitinib for GVHD in Patients < 2 Years Old Shows Variable Pharmacokinetics
February 17th 2023According to findings presented at the 2023 Transplantation & Cellular Therapy Meetings, experts did not identify clear correlation between the pharmacokinetics and pharmacodynamics of ruxolitinib in patients with graft-vs-host-disease.
Read More
Early Trial of Orca-T Produces 100% OS Rate in Hematologic Malignancies and 7/8 Mismatched Donors
February 17th 2023In 8 patients with various hematologic malignancies who received an allogeneic hematopoietic stem cell transplant with 7/8 non-permissive HLA mismatched donors, Orca-T led to a 100% survival rate.
Read More
Early Treatment With Ruxolitinib Induces High Response Rates in SR-aGVHD
February 17th 2023The phase 3 REACH2 trial showed that early treatment with ruxolitinib 10 mg led to higher response rates vs that seen with the best available therapy in patients with grade II-IV steroid-refractory acute graft-vs-host disease.
Read More
Real-World Data Shows Survival Improvement for aGVHD After Ruxolitinib Introduction
February 17th 2023Looking at a retrospective analysis of data from a single-center, the use of ruxolitinib decreased non-relapse mortality and improved overall survival for patients with steroid-refractory acute graft-vs-host-disease.
Read More
PROpel Study of Abiraterone/Olaparib Sustains Benefit in mCRPC
February 17th 2023Though not statistically significant, data from the PROpel study of abiraterone acetate and olaparib were noted to be the longest overall survival results seen in a first-line phase 3 trial in metastatic castration-resistant prostate cancer.
Read More
First-line Treatment With Talazoparib and Enzalutamide Improves rPFS in mCRPC
February 16th 2023Patients with first-line metastatic castration-resistant prostate cancer had improvements in radiographic progression-free survival irrespective of homologous recombination repair status when treated with talazoparib and enzalutamide.
Read More
Phase 3 ZUMA-3 Study of Brexu-cel Elicits Survival Benefit in Relapsed/Refractory B-cell ALL
February 16th 2023Regardless of prior therapies, brexucabtagene autoleucel showed a survival benefit in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, according to subgroup analyses of the phase 3 ZUMA-3 trial.
Read More
Detectable MRD Is Prognostic of Poor HCT Outcomes in Adult ALL
February 16th 2023Risk of relapse was significantly greater for those with acute lymphoblastic leukemia who had low minimal residual disease of less than 10-4 vs those with undetectable MRD, according to results of a retrospective study.
Read More
Zamtocabtagene Autoleucel Shows High Response Rates in Relapsed/Refractory DLBCL
February 16th 2023Findings from the phase 2 DALY II USA trial showed that the 28-day objective response rate was 78% with freshly administered zamtocabtagene autoleucel, exceeding the prespecified efficacy threshold for interim analysis.
Read More